Vitamin D Sarcopenia Meta-analysis: What the Evidence Says

Quick Answer

Vitamin D Sarcopenia Meta-analysis has 1 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• These disorders contribute to a further decline in skeletal muscle mass and function, significantly elevating the risk of sarcopenia. [Wang Lailiang (2026); evidence level 2]
• • Patients with ESRD complicated by sarcopenia may face a higher risk of adverse clinical outcomes. [Wang Lailiang (2026); evidence level 2]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For vitamin D sarcopenia meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Wang Lailiang (2026). Effect of active vitamin D supplementation on muscle mass and function in peritoneal dialysis patients with sarcopenia: a randomized controlled trial. DOI: 10.1038/s41598-026-47141-1. PMCID: PMC13195084. PMID: 41933167. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC13195084/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.